Affiliation:
1. Centre of Quality Management of Medicines, Faculty of Pharmacy Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
2. Department of Pharmacy, Sarawak General Hospital Ministry of Health Malaysia Kuching Sarawak Malaysia
3. Faculty of Pharmacy Universitas Airlangga Surabaya Indonesia
4. Department of Sarawak State Health Ministry of Health Malaysia Kuching Sarawak Malaysia
5. Division of Respiratory Medicine, Department of Internal Medicine Sarawak General Hospital, Ministry of Health Malaysia Kuching Sarawak Malaysia
Abstract
AbstractObjectivesTreatment interruption is associated with poor tuberculosis (TB) treatment outcomes and increased drug resistance. To address the issue, we aimed to investigate the characteristics, predictors and consequences of treatment interruption.MethodsWe conducted a retrospective cohort study by retrieving 4 years (2018–2021) of TB patients' records at 10 public health clinics in Sarawak, Malaysia. Adult patients (≥18 years) with drug‐susceptible TB were selected. Treatment interruption was defined as ≥2 weeks of cumulative interruption during treatment. The Chi‐square test, Mann–Whitney U test, Kaplan–Meier and Cox proportional hazards regression were used to analyse the data, with p < 0.05 being considered statistically significant.ResultsOut of 2953 eligible patients, 475 (16.1%) experienced TB treatment interruption. Interruptions were most frequent during the intensive phase (46.9%, n = 223), with the greatest risk within the first 4 weeks of treatment. The median time to interruption was 2 weeks in the intensive phase and the cumulative interruption probability at the end of the intensive phase was 12.9%. Notably, treatment interruption occurred during both intensive and continuation phases for 144 patients (30.3%), while the remaining 108 (22.7%) experienced interruptions only during the continuation phase with a median time to interruption of 16 weeks. Three predictors were identified to increase the risk of treatment interruption: adverse drug reaction (aHR = 8.53, 95% Cl: 6.73–10.82), smoking (aHR = 2.67, 95% Cl: 2.03–3.53) and illicit drug use (aHR = 1.88, 95% Cl: 1.03–3.45). Conversely, underlying diabetes was associated with a reduced likelihood of treatment interruption (aHR = 0.72, 95% Cl: 0.58–0.90). Treatment interruption led to significant differences in treatment restarts (62.3% vs. 0.7%), changes in medications (47.8% vs. 4.9%), prolonged treatment duration (247 days [IQR = 105] vs. 194 days [IQR = 44.3]) and lower successful outcomes (86.5% vs. 99.9%).ConclusionUnderstanding the temporal characteristics, predictors and negative consequences of treatment interruption can guide the development of time‐relevant approaches to mitigate the problem.
Reference27 articles.
1. The History of Tuberculosis: Past, Present, and Future
2. World Health Organization.Summary of tuberculosis data: tuberculosis in malaysia.2021[7 June 2023]. Available from:https://worldhealthorg.shinyapps.io/TBrief/
3. Tuberculosis: current challenges and beyond